Eli Lilly Q2 Revenue of $22.97 Billion Beats Expectations, Full-Year Revenue Guidance Raised to $85–87 Billion | Earnings Insights
Eli Lilly reported its Q2 2026 earnings, with revenue of $22.97 billion exceeding expectations and adjusted EPS rising 33% year-over-year. The company raised its full-year revenue guidance to $85–87 billion, keeping the lower end of its profit guidance unchanged while slightly lowering the upper end. Buoyed by the positive news, pre-market shares rose approximately 4%
Eli Lilly announced its second-quarter 2026 financial results. Key metrics and full-year outlook are as follows:
- Quarterly Performance: Revenue reached $22.97 billion, significantly surpassing the market expectation of $20.59 billion; adjusted earnings per share (EPS) hit $8.38, up from $6.31 in the same period last year, representing a year-over-year increase of approximately 33%.
- Full-Year Revenue Guidance: Raised to $85–87 billion, compared to the previous forecast of $82–85 billion, with the upper end of the range increased by $2 billion.
- Full-Year Profit Guidance: Adjusted EPS is projected to be $35.50–$36.50. Compared to the previous expectation ($35.50–$37), the lower end of the range remains unchanged, while the upper end was slightly lowered by $0.50.
Buoyed by the positive earnings report, Eli Lilly’s U.S. shares rose approximately 4% in pre-market trading.
Continuously updating
Risk Warning and Disclaimer
The market involves risks, and investment should be approached with caution. This article does not constitute personal investment advice, nor does it take into account the specific investment objectives, financial status, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article align with their specific circumstances. Investment decisions made based on this content are the sole responsibility of the investor.
